

# A meta-analysis of fertility and adverse outcomes in oil- and water-based contrast for hysterosalpingography

Histerosalpingografide kullanılan yağ ve su bazlı kontrast maddenin doğurganlık ve olumsuz sonuçlar üzerine etkisinin meta-analizi

# Stewart Tsui<sup>1</sup>, Ahmed Adel Sofy<sup>2</sup>

<sup>1</sup>Addenbrooke's Hospital, Cambridge, United Kingdom <sup>2</sup>Faculty of Medicine, Fayoum University, Fayoum, Egypt

## Abstract

Infertility is the inability to conceive after one year of regular unprotected intercourse. There is a debate about the therapeutic effect of hysterosalpingography (HSG) and whether the selection of contrast materials makes a difference in the chance of subsequent conception. In this study, we aimed to compare the fertility-enhancing outcomes and adverse effects of oil and water-based contrasts in patients who underwent HSG. This systematic review and meta-analysis was conducted following the PRISMA guidelines. We searched the Web of Science, PubMed, and Scopus until September 2022. We included all primary randomized controlled trials evaluating the fertility-enhancing benefits of HSG in oil-based versus water-based contrast media in women of childbearing age with infertility. Eleven studies with 4,739 patients were selected. The pregnancy rate in the oil group was significantly higher than that in the water group [odds ratio (OR)=1.51 (1.23, 1.86), p<0.0001]. Our meta-analysis favored the oil group in abdominal pain and vaginal bleeding with the odd ratios of 0.73 (0.58, 0.91), (p=0.006) and 0.91 (0.46, 1.81), (p=0.79), respectively. Water-based contrast was associated with less intravasation [OR=2.09 (1.09-4.02), p=0.03]. There were no differences between the contrasts for miscarriage [OR=1.02 (0.71, 1.46), p=0.92], and ectopic pregnancy [OR=0.84 (0.27, 2.63), p=0.77]. HSG with oil-based contrast was related to a higher pregnancy rate, live birth rate, and intravasation rate. While HSG using a water-based contrast medium was associated with increased abdominal discomfort, vaginal bleeding, and the visual-analogue scale pain score.

Keywords: Hysterosalpingography, infertility, contrast media, pregnancy outcome

## Öz

Kısırlık, bir yıl düzenli korunmasız ilişkiden sonra gebe kalamama durumudur. Histerosalpingografinin (HSG) terapötik etkisi ve kontrast madde seçiminin sonraki gebe kalma şansı üzerinde bir fark yaratıp yaratmadığı konusunda bir tartışma vardır. Bu çalışmada, HSG uygulanan hastalarda yağ ve su bazlı kontrastların doğurganlığı artırıcı sonuçlarını ve yan etkilerini karşılaştırmayı amaçladık. Bu sistematik inceleme ve meta-analiz, PRISMA yönergeleri izlenerek yapılmıştır. Eylül 2022'ye kadar Web of Science, PubMed ve Scopus'ta arama yapılmıştır. Kısırlığı olan doğurganlık çağındaki kadınlarda su bazlı ve yağ bazlı kontrast maddelerin kullanıldığı HSG uygulamalarının doğurganlığı artıran faydalarını karşılaştıran tüm primer randomize kontrollü çalışmalar dahil edilmiştir. Dört bin yedi yüz otuz dokuz hasta ile 11 çalışma dahil edilmiştir. Yağ grubundaki gebelik oranı, su grubundan anlamlı olarak yüksekti [tahmini rölatif risk (RR)=1,51 (1,23, 1,86), p<0,0001]. Meta-analizimiz, sırasıyla 0,73 (0,58, 0,91), (0,006) ve 0,91 (0,46, 1,81), (p=0,79) tahmini RR değerleri ile karın ağrısı ve vajinal kanama açısından yağ grubu lehine sonuçlandı. Su bazlı kontrast daha az intravazasyon ile ilişkilendirildi [RR=2,09 (1,09-4,02), p=0,03]. Düşük [RR=1,02 (0,71, 1,46), p=0,92] ve dış gebelik [RR=0,84 (0,27, 2,63), p=0,77] açısından kontrastlar arasında fark yoktu. Yağ bazlı kontrasth HSG, daha yüksek gebelik oranı, canlı doğum oranı ve intravazasyon oranı ile ilişkiliydi. Su bazlı bir kontrast madde kullanan HSG, artmış karın rahatsızlığı, vajinal kanama ve görsel-analog skala ağrı skoru ile ilişkilendirildi.

Anahtar Kelimeler: Histerosalpingografi, infertilite, kontrast madde, gebelik ile sonlanım

Address for Correspondence/Yazışma Adresi: Stewart Tsui MD,

Addenbrooke's Hospital, Cambridge, United Kingdom

Phone: +447415202963 E-mail: stewart.tsuimd@gmail.com ORCID ID: orcid.org/0000-0001-7338-5595 Received/Gelis Tarihi: 03.10.2022 Accepted/Kabul Tarihi: 05.01.2023

<sup>©</sup>Copyright 2023 by Turkish Society of Obstetrics and Gynecology Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

# Introduction

Infertility is the term used to describe a patient who fails to conceive after one year of regular unprotected intercourse. Infertility affects 12% of reproductive-aged women worldwide. Female factors represent about 46% of infertility causes<sup>(1,2)</sup>. Fertilization occurs in the fallopian tubes. Hence, functioning fallopian tubes are essential for conception<sup>(3)</sup>. One-third of infertility cases are attributable to fallopian tube obstruction. Tubal damage frequently a results from adhesions, where proximal tubal occlusion is associated with endometriosis, while distal tubal occlusion is commonly caused by pelvic inflammatory disease<sup>(4)</sup>.

Laparoscopy is the gold standard investigation for the diagnosing of tubal diseases, whereas minimally invasive Hysterosalpingography (HSG) is the first line of radiological evaluation for tubal patency. HSG detects tubal blockage using a contrast medium to visualize the endometrial cavity and fallopian tubes<sup>(5)</sup>. The sensitivity and specificity of HSG in detecting tubal obstruction are 65% and 83%, respectively, with an accuracy rate of  $71\%^{(3,4)}$ .

HSG is often conducted using either water-soluble or oilsoluble contrast as a medium. Although HSG is a diagnostic procedure, there is continuing debate about its therapeutic effect and whether the selection of contrast materials makes a difference in the chance of subsequent conception. Previous randomized controlled trials (RCT) suggested that an oilbased contrast medium is more favorable than a water-based contrast medium due to its fertility-enhancing effects and good image quality<sup>(6,7)</sup>. However, an oil-based contrast medium takes longer to deliver, causing prolonged discomfort and posing a theoretical risk of intravasation and embolism<sup>(8)</sup>. A systematic review with meta-analysis comparing the therapeutic effects of oil-based versus water-based contrast mediums in HSG was published in 2018. This review, with six trials and a total of 2,562 patients, concluded that an oil-based contrast medium has a higher pregnancy rate with an odd ratio of 1.47 compared with a water-based contrast medium<sup>(9)</sup>. However, there are three trials with an unknown bias profile. Since then, several RCTs with sample sizes greater than 1,000 and longer post-HSG follow-ups have been published.

The primary objective of this study was to conduct high evidence systematic review and meta-analysis of the scientific literature to determine the fertility-enhancing outcomes and adverse effects of oil-soluble contrast media versus watersoluble contrast medium in patients undergoing HSG.

## **Materials and Methods**

This systematic review and meta-analysis was prepared based on the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA)<sup>(10)</sup>.

# Literature Searchs and Information Sources

Searches were carried out in the following major electronic databases: Web of Science, PubMed, and Scopus till Sept 2022,

using the following strategy "hysterosalpingography" or "HSG" or "salpingogram" or "hysterosalpingogram" AND "Watersoluble contrast media" or "water-based contrast material (WBCM)" or "oil-soluble contrast media", or "oil-based contrast material (OBCM)" or "lipiodol" or "ethiodol", "Ethiodized" or "iotrolan" or "Tubal flushing". There were no search filters or language limitations.

## Selection Criteria and Eligibility Criteria

We conducted the selection and inclusion process for the study in two stages. We screened the titles and abstracts in the first stage to identify potentially relevant articles. In the second stage, we evaluated relevant articles and included them based on our inclusion criteria. We included all primary RCTs comparing the enhancing-fertility effects of HSG in oil-based contrast medium against a water-based contrast medium in children-bearing aged women with infertility. Any RCTs, which did not evaluate the therapeutic effects of fertility were excluded. We also excluded studies that evaluated the effectiveness of HSG using a single contrast agent without any comparison. Any studies other than RCTs, such as case reviews, case reports, and case series were excluded.

## Data Extraction

We extracted data from the included RCTs and plotted them on an extraction sheet. Other objective outcomes, such as pregnancy outcomes, discomfort, and adverse effects, were recorded. We also collected data on pregnancy rate, live birth, miscarriage, ectopic pregnancy, abnormal pain, vaginal bleeding, intravasation, pain VAS score, and duration between HSG and pregnancy. We also extract relevant data for quality assessments according to the Cochrane assessment tool<sup>(11)</sup>.

## Outcomes

The primary outcome is ongoing pregnancy, which is a positive fetal heartbeat on ultrasound at 12 weeks of gestation. The secondary outcome was the successful conception, which includes (1) gestation sac detection on ultrasonography, (2) live birth (defined as the birth of an infant with the signs of life after 24 weeks of gestation), (3) Miscarriage (defined as no evidence of foetal heartbeat detected on ultrasound or spontaneous loss of pregnancy before 20 weeks of gestation), and (4) ectopic pregnancy (defined as implantation occurs outside the uterus). The degree of pain after HSG is measured by the visual-analogue scale on a scale between 0 and 10, where a high value represents more severe pains.

#### **Quality Assessment**

Only RCTs were included in this study. Thus, they were assessed using the Cochrane risk of bias assessment tool<sup>(11)</sup>. We examined each study for identifiable biases, which are listed as follows: (1) no random sequence generation, (2) no blinding of participants and personnel, (3) no allocation concealment, (4) no blinding of outcome assessment, (5) incomplete outcome data, (6) selective reporting, and (7) other biases. For each

domain, trials could be classified as low, unclear, or high risk of bias.

## Statistical Analysis

Statistical analyses were performed with RevMan 5.4.1 software to assess the retrieved data. Our study included continuous and dichotomous outcomes. We used the inverse variance method to analyze the continuous data using mean difference (MD) and 95% confidence intervals (CI), while dichotomous data were analyzed using Mantel-Haenszel method which were calculated using odds ratio (OR) and 95% CIs. The presence of heterogeneity among the studies was measured by the I<sup>2</sup> and the p-value of the chi-square test. Values of p<0.1 or I<sup>2</sup>>50% were significant indicators of heterogeneity. We tried solving the inconsistency among data using the Cochrane leave-oneout method<sup>(12)</sup>.

# Results

## Search Results and Characteristics of the Included Studies

The search results are illustrated in the PRISMA flow diagram (Figure 1). We included 11 studies<sup>(6,13,14-22)</sup>, which met our inclusion criteria. We analyzed 4,739 patients who underwent HSG either by OBCM or WBCM. The average age of the included patients from both groups was 28.48 years.



Figure 1. Shows the PRISMA flow diagram

Table 1 shows the baseline characteristics of the included studies.

#### Results of the Risk of Bias Assessment

All studies were evaluated according to Cochrane's tool<sup>(23)</sup>. Regarding randomization, six studies<sup>(6,13,15,16,21,22)</sup> reported proper randomization and were categorized as low risk of bias, while the other five studies<sup>(14,17-20)</sup> reported insufficient details regarding the randomization domain therefore they were categorized as unclear risk of bias. Concerning the performance bias, only Dreyer et al.<sup>(15)</sup> were categorized as high risk of bias, the remaining studies were categorized as unclear risk of bias. In detection bias, all studies were categorized as unclear risk of bias, except Zhang et al.<sup>(6)</sup> who reported adequate blinding of the outcome investigators. Figure 2 shows a detailed illustration of the risk of bias of the included studies.



Figure 2. Shows a detailed illustration of the risk of bias of included studies

# **Analysis of Outcome**

## 1. Pregnancy Rate

Eleven studies<sup>(6,13,14-21,22)</sup> reported this outcome. The overall analysis showed that the pregnancy rate was significantly higher in the oil group than in the water group [OR=1.51 (1.23, 1.86), (p<0.0001)]. Data were heterogeneous (p=0.05); I<sup>2</sup>=46% (Figure 3A). We solved the heterogeneity by excluding Spring et al.<sup>(22)</sup> (p=0.85); I<sup>2</sup>=0%. The combined estimate after solving the heterogeneity also favored the oil group [OR=1.64 (1.43, 1.89), (p<0.0001)] (Figure 3B).

# 2. Live Birth

This outcome was reported by four studies<sup>(6,15,20,22)</sup>. We divided the four studies into two subgroups. The first subgroup included two studies that used HSG for therapeutic reasons<sup>(6,15)</sup>. The overall OR in this subgroup favored the oil group significantly [OR=1.55 (1.28, 1.86), (p<0.00001)]. data were homogeneous (p=0.58);  $l^2$ =0%.

Regarding the second subgroup, which included two other studies<sup>(20,22)</sup> that used HSG for diagnostic reasons, there was no significant variation between both groups [OR=1.76 (0.48, 6.44), (p=0.39)]. We faced a significant heterogeneity in this subgroup (p=0.0002); I<sup>2</sup>=93%.

The overall analysis of the four studies showed that live birth is significantly higher in the oil group than in the water group [OR=1.59 (1.09, 2.33), (p=0.02)] (Figure 4).

 Table 1. Shows the baseline characteristics of the included studies

# 3. Miscarriage

2,668 patients were analyzed from four studies<sup>(6,15,19,22)</sup>, which reported the incidence of miscarriage. The combined estimate showed very similar values [OR=1.02 (0.71, 1.46), (p=0.92)]. We found a moderate heterogeneity among studies (p=0.10);  $I^2$ =56% (Figure 5).

# 4. Ectopic Pregnancy

Our analysis of data retrieved from three studies<sup>(15,19,22)</sup> showed that both groups are associated with similar ectopic incidence [OR=0.84 (0.27, 2.63), (p=0.77)]. Our results were homogeneous (p=0.54); I<sup>2</sup>=0% (Figure 6).

# 5. Abnormal Pain

This outcome was reported by two studies<sup>(6,18)</sup>. The overall OR favored the oil group over the water group [OR=0.73 (0.58, 0.91), (p=0.006)]. Data were homogeneous (p=0.31);  $I^2=3\%$  (Figure 7).

# 6. Vaginal Bleeding

Three studies reported vaginal bleeding<sup>(6,17,18)</sup>. We found no variation between both groups [OR=0.91 (0.46, 1.81), (p=0.79)]. Although we found heterogeneity among studies (p=0.01); I<sup>2</sup>=77% (Figure 8A), we could solve this heterogeneity by excluding Lindequist et al.<sup>(17)</sup> (p=0.88); I<sup>2</sup>=0%. The overall analysis after solving heterogeneity showed that the oil group had less incidence of vaginal bleeding [OR=0.67 (0.52, 0.86), (p=0.002)] (Figure 8B).

Study	Country		Sample	size	Age, years r or IQR)	nean (SD	Duration of	infertility	Intervention	
	OBCM	M WBCM O		WBCM	ОВСМ	WBCM	OBCM	WBCM	OBCM	WBCM
Alper <sup>(13)</sup>	Canada		46	60	29.3 (4.6)	29.1 (2.9)	NR	NR	Lipiodol	Renographin
de Boer <sup>(14)</sup>	Netherla	nds	87	88	29 (19-44)	29 (19-44)	37 (26.2)		Lipiodol	Iopamidol
Dreyer <sup>(15)</sup>	Netherla	nds	554	554	32.8 (30-36)	33.0 (30-36)	19.8 (16.0-26.3)	19.6 (15.4-27.4)	Lipiodol	Telebrix
Letterie <sup>(16)</sup>	USA		15	14	27 (3.5)	25 (4.1)	NR	NR	Ethiodized oil	Conray-60
Lindequist <sup>(17)</sup>	Denmark	ζ	121	121	29.9 (21-43)	29.5 (20-40)	40	41	Lipiodol	Iotrolan
Lu <sup>(18)</sup>	China		500	500	29.0 (24.3- 32.0)	27.0 (24.0-32.0)	24 (12-36)	24 (12-36)	Ethiodized poppy seed oil	Ioversol
Mashaqba <sup>(19)</sup>	Jordan		35	40	28 (3)	28 (4)	NR	NR	NR	NR
Rasmussen <sup>(20)</sup>	Denmark	ζ	98	300	22.0 (4.5)	22.4 (5.5)	NR	NR	Lipiodol	Iohexol, ioxaglate, diatrizoate
Schwabe <sup>(21)</sup>	USA		56	65	NR	NR	NR	NR	Ethiodol	Sinografin
Spring <sup>(22)</sup>	USA		273	260	29.3 (4.6)	29.1 (2.9)	37.8 (38.1)	37.5 (36.3)	Lipiodol	Diatrizoate, iodipamide
Zhang <sup>(6)</sup>	China		473	479	30.5 (3.7)	30.8 (3.6)	20.4 (13.32)	20.24 (19.93)	Ethiodized poppyseed oil	Iohexol, Iopromide, Ioverol

OBCM: Oil-based contrast material, WBCM: Water-based contrast material, NR: Unreported, SD: Standard deviation, IQR: Interquartile range.

Α	Oil gro	oup	Water g	roup		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Apler 1986	14	46	15	60	4.7%	1.31 [0.56, 3.09]	
Deboer 1988	30	87	23	88	7.1%	1.49 [0.78, 2.85]	
Dreyer 2017	220	554	161	554	17.9%	1.61 [1.25, 2.06]	
Letterie 1990	6	15	2	14	1.2%	4.00 [0.65, 24.66]	
Lindequist 1994	29	121	24	121	7.7%	1.27 [0.69, 2.35]	
Lu 2022	395	500	351	500	16.5%	1.60 [1.20, 2.13]	
Mashaqba 2006	8	35	4	40	2.3%	2.67 [0.73, 9.78]	
Rasmussen 1991	32	98	50	300	9.5%	2.42 [1.44, 4.08]	
Schwabe 1983	11	56	7	65	3.5%	2.03 [0.73, 5.64]	
Spring 2000	74	273	84	260	13.5%	0.78 [0.54, 1.13]	+
Zhang 2022	136	473	96	479	16.0%	1.61 [1.19, 2.17]	
Total (95% CI)		2258		2481	100.0%	1.51 [1.23, 1.86]	•
Total events	955		817				
Heterogeneity: Tau <sup>2</sup> =	0.05; Ch	i <sup>2</sup> = 18.	41, df = 1	0 (P = 0	.05); l <sup>2</sup> = 4	6%	
Test for overall effect:	Z = 3.92	(P < 0.0	0001)				U.1 U.2 U.5 1 2 5 10 Water group Oil group
B	Oil grou	up	Water gr	oup		Odds Ratio	Odds Ratio
B Study or Subgroup	Oil grou Events	up Total	Water gr Events	roup Total	Weight	Odds Ratio M-H, Random, 95% Cl	Odds Ratio M-H, Random, 95% Cl
B Study or Subgroup Apler 1986	Oil grou Events 14	up Total 46	Water gr Events 15	roup Total 60	Weight 2.7%	Odds Ratio M-H, Random, 95% Cl 1.31 [0.56, 3.09]	Odds Ratio M-H, Random, 95% Cl
B Study or Subgroup Apler 1986 Deboer 1988	Oil grou Events 14 30	up Total 46 87	Water gr Events 15 23	roup Total 60 88	Weight 2.7% 4.6%	Odds Ratio M-H, Random, 95% Cl 1.31 [0.56, 3.09] 1.49 [0.78, 2.85]	Odds Ratio M-H, Random, 95% CI
B Study or Subgroup Apler 1986 Deboer 1988 Dreyer 2017	Oil grou Events 14 30 220	up Total 46 87 554	Water gr Events 15 23 161	Total 60 88 554	Weight 2.7% 4.6% 31.3%	Odds Ratio M-H, Random, 95% CI 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06]	Odds Ratio M-H, Random, 95% CI
B Study or Subgroup Apler 1986 Deboer 1988 Dreyer 2017 Letterie 1990	Oil grou Events 14 30 220 6	up Total 46 87 554 15	Water gr Events 15 23 161 2	roup Total 60 88 554 14	Weight 2.7% 4.6% 31.3% 0.6%	Odds Ratio <u>M-H, Random, 95% Cl</u> 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06] 4.00 [0.65, 24.66]	Odds Ratio M-H, Random, 95% CI
B Study or Subgroup Apler 1986 Deboer 1988 Dreyer 2017 Letterie 1990 Lindequist 1994	Oil grou Events 14 30 220 6 29	up <u>Total</u> 46 87 554 15 121	Water gr Events 15 23 161 2 24	Total 60 88 554 14 121	Weight 2.7% 4.6% 31.3% 0.6% 5.2%	Odds Ratio M-H, Random, 95% Cl 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06] 4.00 [0.65, 24.66] 1.27 [0.69, 2.35]	Odds Ratio M-H, Random, 95% CI
B Study or Subgroup Apler 1986 Deboer 1988 Dreyer 2017 Letterie 1990 Lindequist 1994 Lu 2022	Oil grou Events 14 30 220 6 29 395	up <u>Total</u> 46 87 554 15 121 500	Water gr Events 15 23 161 2 24 351	Total 60 88 554 14 121 500	Weight 2.7% 4.6% 31.3% 0.6% 5.2% 23.6%	Odds Ratio M-H, Random, 95% Cl 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06] 4.00 [0.65, 24.66] 1.27 [0.69, 2.35] 1.60 [1.20, 2.13]	Odds Ratio M-H, Random, 95% CI
B Study or Subgroup Apler 1986 Deboer 1988 Dreyer 2017 Letterie 1990 Lindequist 1994 Lu 2022 Mashaqba 2006	Oil grou Events 14 30 220 6 29 395 8	up <u>Total</u> 46 87 554 15 121 500 35	Water gr Events 15 23 161 2 24 351 4	Total 60 88 554 14 121 500 40	Weight 2.7% 4.6% 31.3% 0.6% 5.2% 23.6% 1.2%	Odds Ratio <u>M-H, Random, 95% Cl</u> 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06] 4.00 [0.65, 24.66] 1.27 [0.69, 2.35] 1.60 [1.20, 2.13] 2.67 [0.73, 9.78]	Odds Ratio M-H, Random, 95% CI
B Study or Subgroup Apler 1986 Deboer 1988 Dreyer 2017 Letterie 1990 Lindequist 1994 Lu 2022 Mashaqba 2006 Rasmussen 1991	Oil grou Events 14 30 220 6 29 395 8 32	up Total 46 87 554 15 121 500 35 98	Water gr Events 15 23 161 2 24 351 4 50	Total 60 88 554 14 121 500 40 300	Weight 2.7% 4.6% 31.3% 0.6% 5.2% 23.6% 1.2% 7.2%	Odds Ratio <u>M-H, Random, 95% CI</u> 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06] 4.00 [0.65, 24.66] 1.27 [0.69, 2.35] 1.60 [1.20, 2.13] 2.67 [0.73, 8.78] 2.42 [1.44, 4.08]	Odds Ratio M-H, Random, 95% CI
B Study or Subgroup Apler 1986 Deboer 1988 Dreyer 2017 Letterie 1990 Lindequist 1994 Lu 2022 Mashaqba 2006 Rasmussen 1991 Schwabe 1983	Oil grou Events 14 30 220 6 29 395 8 32 11	up Total 46 87 554 15 121 500 35 98 56	Water gr Events 15 23 161 2 24 351 4 50 7	Total 60 88 554 14 121 500 40 300 65	Weight 2.7% 4.6% 31.3% 0.6% 5.2% 23.6% 1.2% 7.2% 1.9%	Odds Ratio M-H, Random, 95% Cl 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06] 4.00 [0.65, 24.66] 1.27 [0.69, 2.35] 1.60 [1.20, 2.13] 2.67 [0.73, 9.78] 2.42 [1.44, 4.08] 2.03 [0.73, 5.64]	Odds Ratio M-H, Random, 95% CI
B Study or Subgroup Apier 1986 Deboer 1988 Drever 2017 Letterie 1990 Lindequist 1994 Lu 2022 Mashaqba 2006 Rasmussen 1991 Schwabe 1983 Spring 2000	Oil grou Events 14 30 220 6 29 395 8 32 11 74	up <u>Total</u> 46 87 554 121 500 35 98 56 273	Water gr Events 15 23 161 2 24 351 4 50 7 84	Total 60 88 554 14 121 500 40 300 65 260	Weight 2.7% 4.6% 31.3% 0.6% 5.2% 23.6% 1.2% 7.2% 1.9% 0.0%	Odds Ratio M-H, Random, 95% Cl 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06] 4.00 [0.65, 24.66] 1.27 [0.69, 2.35] 1.60 [1.20, 2.13] 2.67 [0.73, 9.78] 2.42 [1.44, 4.08] 2.03 [0.73, 5.64] 0.78 [0.54, 1.13]	Odds Ratio M-H, Random, 95% CI
B Study or Subgroup Apler 1986 Deboer 1988 Dreyer 2017 Letterie 1990 Lindequist 1994 Lu 2022 Mashaqba 2006 Rasmussen 1991 Schwabe 1983 Spring 2000 Zhang 2022	Oil grou Events 14 30 220 6 29 395 8 32 11 74 136	up <u>Total</u> 46 87 554 121 500 35 98 56 273 473	Water gr Events 15 23 161 2 24 351 4 50 7 84 96	Total           60           88           554           14           121           500           40           300           65           260           479	Weight 2.7% 4.6% 31.3% 0.6% 5.2% 23.6% 1.2% 7.2% 1.9% 0.0% 21.8%	Odds Ratio M-H, Random, 95% Cl 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06] 4.00 [0.65, 24.66] 1.27 [0.69, 2.35] 1.60 [1.20, 2.13] 2.67 [0.73, 8.78] 2.42 [1.44, 4.08] 2.03 [0.73, 5.64] 0.78 [0.54, 1.13] 1.61 [1.19, 2.17]	Odds Ratio M-H, Random, 95% CI
B Study or Subgroup Apler 1986 Deboer 1988 Dreyer 2017 Letterie 1990 Lindequist 1994 Lu 2022 Mashaqba 2006 Rasmussen 1991 Schwabe 1983 Spring 2000 Zhang 2022 Total (95% CI)	Oil grou Events 14 30 220 6 29 395 8 325 8 32 11 74 136	up Total 46 87 554 15 121 500 35 98 56 273 473 1985	Water gr Events 15 23 161 2 24 351 4 50 7 84 96	Total 60 88 554 14 121 500 40 300 65 260 479 2221	Weight 2.7% 4.6% 31.3% 0.6% 5.2% 23.6% 1.2% 7.2% 1.9% 0.0% 21.8% 100.0%	Odds Ratio M-H, Random, 95% Cl 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06] 4.00 [0.65, 24.66] 1.27 [0.69, 2.35] 1.60 [1.20, 2.13] 2.67 [0.73, 9.78] 2.42 [1.44, 4.08] 2.03 [0.73, 5.64] 0.78 [0.54, 1.13] 1.61 [1.19, 2.17] 1.64 [1.43, 1.89]	Odds Ratio M-H, Random, 95% CI
B Study or Subgroup Apler 1986 Deboer 1988 Dreyer 2017 Letterie 1990 Lindequist 1994 Lu 2022 Mashaqba 2006 Rasmussen 1991 Schwabe 1983 Spring 2000 Zhang 2022 Total (95% CI) Total events	Oil grou Events 14 30 220 6 290 395 8 32 11 74 136 881	up <u>Total</u> 46 87 554 15 121 500 35 98 56 273 473 <b>1985</b>	Water gr Events 15 23 161 24 351 4 50 7 84 96 733	Total           60           88           554           14           121           500           40           300           65           260           479           2221	Weight 2.7% 4.6% 31.3% 0.6% 5.2% 23.6% 1.2% 7.2% 1.9% 0.0% 21.8% 100.0%	Odds Ratio M-H, Random, 95% Cl 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06] 4.00 [0.65, 24.66] 1.27 [0.69, 2.35] 1.60 [1.20, 2.13] 2.67 [0.73, 9.78] 2.42 [1.44, 4.08] 2.03 [0.73, 5.64] 0.78 [0.54, 1.13] 1.61 [1.19, 2.17] 1.64 [1.43, 1.89]	Odds Ratio M-H, Random, 95% CI
B           Study or Subgroup           Apier 1986           Deboer 1988           Dreyer 2017           Letterie 1990           Lindequist 1994           Lu 2022           Mashaqba 2006           Rasmussen 1991           Schwabe 1983           Spring 2000           Zhang 2022           Total (95% CI)           Total events           Heterogeneity: Tau <sup>2</sup> = 1	Oil grou Events 14 30 220 6 295 395 8 32 11 74 136 881 0.00; Chi <sup>2</sup>	up <u>Total</u> 46 87 554 15 121 500 35 98 56 273 473 <b>1985</b> <sup>2</sup> = 4.86	Water gr Events 15 23 161 2 24 351 4 50 7 84 96 733 , df= 9 (P	Total 60 88 554 14 121 500 40 300 65 260 479 2221 = 0.85)	Weight 2.7% 4.6% 31.3% 0.6% 23.6% 1.2% 7.2% 1.9% 0.0% 21.8% 100.0% ; I <sup>2</sup> = 0%	Odds Ratio M-H, Random, 95% Cl 1.31 [0.56, 3.09] 1.49 [0.78, 2.85] 1.61 [1.25, 2.06] 4.00 [0.65, 24.66] 1.27 [0.69, 2.35] 1.60 [1.20, 2.13] 2.67 [0.73, 9.78] 2.42 [1.44, 4.08] 2.03 [0.73, 5.64] 0.78 [0.54, 1.13] 1.61 [1.19, 2.17] 1.64 [1.43, 1.89]	Odds Ratio M-H, Random, 95% CI

Figure 3. Shows the outcome of pregnancy rate-part A includes 11 studies<sup>(6,13,14-22)</sup> & part B excludes Spring et al.<sup>(22)</sup>



Figure 4. Shows the outcome of live birth

## 7. Intravasation

2,516 patients were analyzed from five studies<sup>(6,13,15,17,19)</sup> that investigated this side effect. We found that HSG by waterbased contrast was associated with a lower incidence of intravasation than oil-based contrast [OR=2.09 (1.09, 4.02),

(p=0.03)]. The overall analysis was homogenous (p=0.33);  $I^2=12\%$  (Figure 9).

	Oil group Water group			roup		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Dreyer 2017	29	554	31	554	49.8%	0.93 [0.55, 1.57]	
Mashaqba 2006	0	35	0	40		Not estimable	
Spring 2000	19	273	24	260	38.8%	0.74 [0.39, 1.38]	
Zhang 2022	16	473	7	479	11.4%	2.36 [0.96, 5.79]	
Total (95% CI)		1335		1333	100.0%	1.02 [0.71, 1.46]	-
Total events	64		62				
Heterogeneity: Chi <sup>2</sup> =	4.52, df=	2 (P =	0.10); I <sup>2</sup> =	56%			
Test for overall effect:	Z = 0.10	(P = 0.9	92)				0.2 0.5 1 2 5 Oil group Water group

#### Figure 5. Shows the outcome of miscarriage

	Oil gro	oup	Water g	roup		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Dreyer 2017	2	554	2	554	30.6%	1.00 [0.14, 7.12]	<b>+</b>
Mashaqba 2006	1	35	0	40	6.9%	3.52 [0.14, 89.27]	
Spring 2000	2	273	4	260	62.5%	0.47 [0.09, 2.60]	
Total (95% CI)		862		854	100.0%	0.84 [0.27, 2.63]	
Total events	5		6				
Heterogeneity: Chi <sup>2</sup> =	1.22, df =	: 2 (P =	0.54); I <sup>z</sup> =	0%			
Test for overall effect:	Z = 0.29	(P = 0.7)	'7)				Oil group Water group

#### Figure 6. Shows the outcome of ectopic pregnancy

	Oil gro	oup	p Water group			Odds Ratio		Odds	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixe	d, 95% Cl		
Lu 2022	33	500	36	500	19.1%	0.91 [0.56, 1.49]					
Zhang 2022	180	491	225	491	80.9%	0.68 [0.53, 0.88]		<u> </u>			
Total (95% CI)		991		991	100.0%	0.73 [0.58, 0.91]					
Total events	213		261								
Heterogeneity: Chi <sup>2</sup> =	1.03, df =	: 1 (P =	0.31); I <sup>z</sup> =	: 3%				7	1	5	+
Test for overall effect:	Z= 2.76	(P = 0.0	)06)				0.0 0	Oil group	Water grou	.o .p	2

#### Figure 7. Shows the outcome of abnormal pain

Α	Oil gr	oup	Water	group		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Lindequist 1994	63	122	50	123	38.7%	1.56 [0.94, 2.58]	
Lu 2022	3	500	5	500	15.5%	0.60 [0.14, 2.51]	
Zhang 2022	170	491	217	491	45.8%	0.67 [0.52, 0.87]	
Total (95% CI)		1113		1114	100.0%	0.91 [0.46, 1.81]	•
Total events	236		272				
Heterogeneity: Tau <sup>2</sup> =	= 0.25; Ch	i <sup>2</sup> = 8.7	'0, df = 2 (	P = 0.01	); $l^2 = 779$	Ж	
Test for overall effect	Z=0.27	(P = 0.	79)				U.U1 U.1 1 10 100 Oil group Water group
							Oligioup Water group
В	Oil are	up.	Water ar	oun		Odde Patio	Odde Patio
B Study or Subarrow	Oil gro	up	Water gr	oup	Maight	Odds Ratio	Odds Ratio
B Study or Subgroup	Oil gro Events	up Total	Water gr Events	oup Total	Weight	Odds Ratio M-H, Random, 95% Cl	Odds Ratio M-H, Random, 95% Cl
B Study or Subgroup Lindequist 1994	Oil gro Events 63	up Total 122	Water gr Events 50	oup Total 123	Weight 0.0%	Odds Ratio M-H, Random, 95% Cl 1.56 [0.94, 2.58]	Odds Ratio M-H, Random, 95% Cl
B <u>Study or Subgroup</u> Lindequist 1994 Lu 2022	Oil gro Events 63 3	up Total 122 500	Water gr Events 50 5	Total 123 500	Weight 0.0% 3.1%	Odds Ratio M-H, Random, 95% Cl 1.56 [0.94, 2.58] 0.60 [0.14, 2.51]	Odds Ratio M-H, Random, 95% Cl
B <u>Study or Subgroup</u> Lindequist 1994 Lu 2022 Zhang 2022	Oil gro Events 63 3 170	up Total 122 500 491	Water gr Events 50 5 217	Total 123 500 491	Weight 0.0% 3.1% 96.9%	Odds Ratio M-H, Random, 95% CI 1.56 [0.94, 2.58] 0.60 [0.14, 2.51] 0.67 [0.52, 0.87]	Odds Ratio M-H, Random, 95% Cl
B Study or Subgroup Lindequist 1994 Lu 2022 Zhang 2022	Oil gro Events 63 3 170	up Total 122 500 491	Water gr Events 50 5 217	roup Total 123 500 491	Weight 0.0% 3.1% 96.9%	Odds Ratio M-H, Random, 95% Cl 1.56 [0.94, 2.58] 0.60 [0.14, 2.51] 0.67 [0.52, 0.87]	Odds Ratio M-H, Random, 95% CI
B <u>Study or Subgroup</u> Lindequist 1994 Lu 2022 Zhang 2022 Total (95% CI)	Oil gro Events 63 3 170	up Total 122 500 491 991	Water gr Events 50 5 217	Total 123 500 491 991	Weight 0.0% 3.1% 96.9% 100.0%	Odds Ratio M-H, Random, 95% CI 1.56 [0.94, 2.58] 0.60 [0.14, 2.51] 0.67 [0.52, 0.87] 0.67 [0.52, 0.86]	Odds Ratio M-H, Random, 95% CI
B <u>Study or Subgroup</u> Lindequist 1994 Lu 2022 Zhang 2022 Total (95% CI) Total events	Oil gro Events 63 3 170 173	up Total 122 500 491 991	Water gr Events 50 5 217 222	Total 123 500 491 991	Weight 0.0% 3.1% 96.9% 100.0%	Odds Ratio M-H, Random, 95% CI 1.56 [0.94, 2.58] 0.60 [0.14, 2.51] 0.67 [0.52, 0.87] 0.67 [0.52, 0.86]	Odds Ratio M-H, Random, 95% CI
B <u>Study or Subgroup</u> Lindequist 1994 Lu 2022 Zhang 2022 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> =	Oil gro Events 63 3 170 173 0.00; Chi <sup>2</sup>	up <u>Total</u> 122 500 491 991 <sup>2</sup> = 0.02	Water gr Events 50 5 217 222 c, df = 1 (P	Total 123 500 491 991 = 0.88)	Weight 0.0% 3.1% 96.9% 100.0%	Odds Ratio M-H, Random, 95% Cl 1.56 [0.94, 2.58] 0.60 [0.14, 2.51] 0.67 [0.52, 0.87] 0.67 [0.52, 0.86]	Odds Ratio M-H, Random, 95% CI
B <u>Study or Subgroup</u> Lindequist 1994 Lu 2022 Zhang 2022 Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect :2	Oil gro Events 63 3 170 173 0.00; Chi <sup>2</sup> Z = 3.14 (I	up <u>Total</u> 122 500 491 <b>991</b> <sup>2</sup> = 0.02 P = 0.01	Water gr Events 50 5 217 222 c, df = 1 (P 02)	Total 123 500 491 991 = 0.88)	Weight 0.0% 3.1% 96.9% 100.0%	Odds Ratio M-H, Random, 95% CI 1.56 [0.94, 2.58] 0.60 [0.14, 2.51] 0.67 [0.52, 0.87] 0.67 [0.52, 0.86]	Odds Ratio M-H, Random, 95% CI

Figure 8. Shows the outcome of vaginal bleeding-part A includes three studies<sup>(6,18,19)</sup> & part B excludes Lindequist et al.<sup>(17)</sup>

## 8. Pain VAS Scores

Three studies<sup>(6,13,15)</sup> assessed the pain VAS score among the included patients. The overall mean difference showed that the pain VAS score was significantly lower in the oil group than in

the water group [MD=-0.40 (-0.56, -0.24), (p<0.00001)]. We found no heterogeneity among data (p=0.25);  $I^2$ =28% (Figure 10).

#### 9. Duration Between HSG and Pregnancy (Weeks)

This outcome was reported by four studies<sup>(6,15,18,19)</sup>. The combined estimate showed no difference between both groups [MD=-1.08 (-3.43, 1.28), (p=0.37)]. The analysis showed major heterogeneity (p=0.0002); I<sup>2</sup>=85% (Figure 11A). We could solve this heterogeneity by excluding Zhang et al.<sup>(6)</sup> (p=0.19); I<sup>2</sup>=41%. The overall analysis after solving this heterogeneity also showed similar values in both groups [MD=0.41 (-0.72, 1.55), (p=0.48)] (Figure 11B).

#### Discussion

This is the most recent meta-analysis comparing the results of HSG performed with OBCM and WBCM. Our meta-analysis revealed that the pregnancy rate in patients who had HSG with OBCM was 1.51 times greater than in those who had WBCM. This agrees with previous studies. In terms of pregnancy outcome, patients receiving OBCM are more likely to deliver a live birth than those receiving WBCM. There were no statistically significant differences between these two contrast materials for patients with miscarriage and ectopic pregnancy. There were



#### Figure 9. Shows the outcome of intravasation

	Oil group			Water group				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Apler 1986	2.9	0.9	46	3.2	1.6	60	10.7%	-0.30 [-0.78, 0.18]	
Dreyer 2017	4.7	2.5	554	4.9	2.75	554	25.8%	-0.20 [-0.51, 0.11]	
Zhang 2022	1.8	1.5	473	2.3	1.6	479	63.6%	-0.50 [-0.70, -0.30]	
Total (95% CI)			1073			1093	100.0%	-0.40 [-0.56, -0.24]	•
Heterogeneity: Chi <sup>2</sup> = Test for overall effect:	2.76, df Z = 5.01	= 2 (I (P <	P = 0.2 0.0000	5); I² = 2 01)	8%				-1 -0.5 0 0.5 1 Oil group Water group

#### Figure 10. Shows the outcome of pain VAS score

VAS: Visual analog scale

Α	Oil group Water					р		Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
Dreyer 2017	39.86	1.56	554	39.6	1.56	554	37.8%	0.26 [0.08, 0.44]	•	_
Lu 2022	56.42	103.9	500	69.44	153.4	500	2.0%	-13.02 [-29.26, 3.22]		
Mashaqba 2006	9	4	35	8	3	40	32.1%	1.00 [-0.62, 2.62]		
Zhang 2022	41.7	18.5	473	46.1	16.8	479	28.2%	-4.40 [-6.65, -2.15]	-	
Total (95% CI)			1562			1573	100.0%	-1.08 [-3.43, 1.28]	•	
Heterogeneity: Tau <sup>2</sup> =	3.81; Cł	ni² = 19.	85, df=	3 (P =	0.0002)	; I <sup>2</sup> = 85	5%			
Test for overall effect:	Z = 0.90	(P = 0.3	37)						-20 -10 0 10 20 Oil group Water group	
-	Oil group Water group									
B	0	il group		Wa	ter grou	Ip		Mean Difference	Mean Difference	
B Study or Subgroup	Oi Mean	il group SD	Total	Wa Mean	ter grou SD	ip Total	Weight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl	
B Study or Subgroup Dreyer 2017	Oi Mean 39.86	il group SD 1.56	Total 554	Wa Mean 39.6	ter grou SD 1.56	ip Total 554	Weight 70.4%	Mean Difference IV, Random, 95% CI 0.26 [0.08, 0.44]	Mean Difference IV, Random, 95% Cl	_
B Study or Subgroup Dreyer 2017 Lu 2022	Oi Mean 39.86 56.42	il group SD 1.56 103.9	Total 554 500	Wa Mean 39.6 69.44	ter grou <u>SD</u> 1.56 153.4	1 <b>p</b> Total 554 500	Weight 70.4% 0.5%	Mean Difference IV, Random, 95% CI 0.26 [0.08, 0.44] -13.02 [-29.26, 3.22]	Mean Difference IV, Random, 95% Cl	_
B Study or Subgroup Dreyer 2017 Lu 2022 Mashaqba 2006	Oi Mean 39.86 56.42 9	il group SD 1.56 103.9 4	Total 554 500 35	Wa Mean 39.6 69.44 8	ter grou SD 1.56 153.4 3	10 Total 554 500 40	Weight 70.4% 0.5% 29.1%	Mean Difference IV, Random, 95% CI 0.26 [0.08, 0.44] -13.02 [-29.26, 3.22] 1.00 [-0.62, 2.62]	Mean Difference IV, Random, 95% Cl	
B Study or Subgroup Dreyer 2017 Lu 2022 Mashaqba 2006 Zhang 2022	Oi Mean 39.86 56.42 9 41.7	il group SD 1.56 103.9 4 18.5	Total 554 500 35 473	Wa <u>Mean</u> 39.6 69.44 8 46.1	ter grou SD 1.56 153.4 3 16.8	10 Total 554 500 40 479	Weight 70.4% 0.5% 29.1% 0.0%	Mean Difference IV, Random, 95% CI 0.26 [0.08, 0.44] -13.02 [-29.26, 3.22] 1.00 [-0.62, 2.62] -4.40 [-6.65, -2.15]	Mean Difference IV, Random, 95% Cl	_
B Study or Subgroup Dreyer 2017 Lu 2022 Mashaqba 2006 Zhang 2022 Total (95% CI)	0 <u>Mean</u> 39.86 56.42 9 41.7	il group <u>SD</u> 1.56 103.9 4 18.5	Total 554 500 35 473 1089	Wa <u>Mean</u> 39.6 69.44 8 46.1	ter grou <u>SD</u> 1.56 153.4 3 16.8	10 Total 554 500 40 479 1094	Weight 70.4% 0.5% 29.1% 0.0% 100.0%	Mean Difference IV, Random, 95% CI 0.26 [0.08, 0.44] -13.02 [-29.26, 3.22] 1.00 [-0.62, 2.62] -4.40 [-6.65, -2.15] 0.41 [-0.72, 1.55]	Mean Difference IV, Random, 95% Cl	_
B <u>Study or Subgroup</u> Dreyer 2017 Lu 2022 Mashaqba 2006 Zhang 2022 Total (95% CI) Heterogeneity: Tau <sup>2</sup> =	0 <u>Mean</u> 39.86 56.42 9 41.7 0.47; C	il group SD 1.56 103.9 4 18.5 hi <sup>2</sup> = 3.3	Total 554 500 35 473 1089 6, df =	Wa <u>Mean</u> 39.6 69.44 8 46.1 2 (P = 0	ter grou SD 1.56 153.4 3 16.8 .19); I <sup>2</sup> =	Total 554 500 40 479 1094 = 41%	Weight 70.4% 0.5% 29.1% 0.0% 100.0%	Mean Difference IV, Random, 95% CI 0.26 [0.08, 0.44] -13.02 [-29.26, 3.22] 1.00 [-0.62, 2.62] -4.40 [-6.65, -2.15] 0.41 [-0.72, 1.55]	Mean Difference IV, Random, 95% Cl	

**Figure 11.** Shows the outcome of duration between HSG and pregnancy (weeks)-Part A includes four studies<sup>(6,16,19,20)</sup> & Part B excludes Zhang et al.<sup>(6)</sup>

HSG: Hysterosalpingography

diverse outcomes when it came to side effects. The oil group had a lower incidence of vaginal bleeding and abdominal pain than the water group, although OBCM was associated with more incidence of developing intravasation than WBCM.

A previously published meta-analysis, which was conducted in 2018, included six RCTs and 2,564 patients<sup>(9)</sup>. They showed that women who received HSG with OBCM had a greater pregnancy rate than women who underwent HSG with WBCM, but there were no statistically significant differences between patients with miscarriage and ectopic pregnancy. However, the population size was insufficient for evaluating the risk of publication bias and rare pregnancy outcomes, such as miscarriage and ectopic pregnancy. Two studies also included patients with co-treatment, which may have contributed to pregnancy outcome measurements. Another meta-analysis released in 2019 investigated the effectiveness of HSG on fertility outcomes using different materials<sup>(24)</sup>. However, most RCTs compare the fertility outcome of a single contrast medium to control. There are only five RCTs that directly compare WBCM and OBCM.

Early studies in the 1980s revealed that patients who underwent HSG with OBCM had a higher pregnancy rate than those who received HSG with WBCM. However, no statistically significant variations in pregnancy outcomes were found until two RCTs in the 1990s<sup>(16,20)</sup>. These findings are consistent with our metaanalysis finding of an odd ratio of 1.51 in OBCM versus WBCM. The mechanisms of fertility-enhancing effects in an oil-based contrast medium remain unknown. It is theorized that the bacteriostatic and fibrinolytic properties of oil-based contrast media minimize edema on the mucus membrane. In addition to the stimulation of ciliary activity, mechanical cleansing of the uterine cavity and fallopian tubes makes the environment more conducive to conception and spermatozoa penetration.

Despite its therapeutic potential, OBCM is associated with a higher risk of overall side effects. The introduction of foreign substances into the bloodstream via blood or lymph vessels is known as intravasation. Previous studies have shown that the risk of intravasation in OBCMs is higher than in WBCMs<sup>(25)</sup>. This is consistent with our research, which found an odd ratio of 2. Embolism is one of the most serious complications of intravasation. A systematic review of 31 studies involving 19,339 people<sup>(8)</sup> showed that only 18 women experienced oil embolism, with four cases including embolism to the brain and retina. None of the patients ended up with long-term complications.

The primary objective of pregnancy is a live birth. However, there are other possible pregnancy outcomes, such as miscarriage and ectopic pregnancy. A five-year follow-up study showed that OBCM improves live birth by 7.5% compared to WBCM (OR=1.11), and our findings support this with a stronger association (OR=1.51). Patients who received HSG for infertility have a baseline risk of miscarriage and ectopic pregnancy<sup>(26)</sup>. The same study with five years follow-up also

showed that the association between miscarriage and ectopic pregnancy in the OBCM group was not statistically significant compared with the WBCM group<sup>(27)</sup>. OBCM could increase the rate of maternal subclinical hypothyroidism (SCH) because of its high iodine content. A large dose of OBCM is also related to thyroid dysfunction in Neonates<sup>(28)</sup>. However, another RCT on 140 neonates found no difference in thyroid function between OBCM and WBCM<sup>(29)</sup>. Women in early pregnancy with SCH had a higher chance of miscarriage<sup>(30,31)</sup>. A study suggested that up to 25% of HSG patients with OBCM-developed SCH, compared with 10% of those with WBCM(32). The risk factors for ectopic pregnancy vary by the patient, including a history of pelvic inflammatory disease or surgery. Literature on ectopic pregnancy following HSG is limited, and our analysis showed that both materials are associated with the same ectopic incidence. The prevalence of miscarriage and ectopic pregnancy following HSG requires further research.

Most studies examined pregnancy or conception at a specific time but not cumulatively. An RCT of 5 years follow-up confirmed that the OBCM group had a higher cumulative spontaneous pregnancy rate than the WBCM group<sup>(27)</sup>. Another RCT concluded that the median time between HSG and pregnancy for OBCM and WBCM is 13 and 16 months, respectively<sup>(18)</sup>. However, our analysis with four RCTs found no statistically significant differences between OBCM and WBCM for the duration from HSG until pregnancy. The fertility-enhancing effect of HSG in the OBCM lasts for at least a year and is reduced over time. The therapeutic effects are expected to return to baseline in 2 years. The diminishing therapeutic effects in OBCM after an HSG may be attributed to other measures taken by patients to address their infertility problems, such as weight loss, starting IVF, or smoking cessation<sup>(18)</sup>.

Lower abdomen pain and vaginal bleeding are other significant complications of HSG(33). Only half of the HSG patients complained of abdominal pain and vaginal bleeding. Most pain is resolved within 24 h, and the amount of blood is typically less than menstruation<sup>(17)</sup>. No pre-procedural risk factors, including volume of contrast used, osmolality, or viscosity of contrast, are identified with worsening pain during HSG<sup>(34)</sup>. The expansion following contrast administration causes visceral sensory nerve stimulation, release of local prostaglandin and, subsequently, uterine contraction<sup>(35)</sup>. However, women with an abnormal HSG result reported more pain during and 30 min following treatment<sup>(36)</sup>. Previous literature suggested that OBCM resulted in less pain throughout the procedure. The incidence of delayed pain following HSG is lower in the OBCM group, which is consistent with our findings. In terms of vaginal bleeding, previous studies have shown that the occurrence and duration of vaginal bleeding are more significant in HSG patients with WBCM<sup>(17)</sup>. Our analysis supports this finding. The cause of vaginal bleeding after HSG still requires additional investigation. One explanation is that the overflow of OBCM in

the uterine umbrella tip region is gentler and less stimulating the peritoneum, resulting in less pain and vaginal hemorrhage<sup>(35)</sup>.

Multiple RCTs support the use of ethiodized poppyseed oilbased contrast due to its potential therapeutic effects and common adverse effects, which is the material of choice for HSG<sup>(6,17)</sup>. Hysterosalpingo-foam sonography (Hyfosy) is a newly evolving alternative to HSG for determining tubal patency. The sensitivity of Hyfosy is similar to that of HSG, whereas one of the primary advantages of Hyfosy over HSG is the absence of radiation exposure, which removes patient anxiety and the risk of undetected early pregnancy<sup>(37,38)</sup>. However, no therapeutic effects of Hyfosy on infertility have yet been identified.

#### Study Limitations

The main limitation of our study was the heterogeneity found in some outcomes. However, we could solve them either by the leave-one-out method or by conducting a subgroup analysis. Five new RCTs with a total of 2,177 individuals have been included in our meta-analysis, including three and five-year follow-up studies in our qualitative synthesis and more recent studies with participants greater than 1,000. A larger population size enables us to provide a more accurate evaluation for uncommon pregnancy outcomes, such as miscarriage and ectopic pregnancy, and rare adverse effects, such as intravasation and embolism. This also allowed us to examine publication bias. There are several confounding factors during pregnancy. Increasing the number of RTCs will enable us to examine the influence of each variable and better understand its adverse effects.

## Conclusion

To conclude, HSG using OBCM was associated with a higher incidence of pregnancy rate, live birth, and intravasation. While HSG using WBCM was associated with more abdominal pain, vaginal bleeding, and the overall VAS pain score. We found no significant difference between the groups regarding miscarriage, ectopic pregnancy, and the duration of HSG and pregnancy.

#### Ethics

Peer-review: Externally and internally peer-reviewed.

## Authorship Contributions

Concept: A.A.S., Design: A.A.S., Data Collection or Processing: A.A.S., Analysis or Interpretation: A.A.S., Processing and Interpretation: S.T., Writing: S.T.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

#### References

 Datta J, Palmer MJ, Tanton C, Gibson LJ, Jones KG, Macdowall W, et al. Prevalence of infertility and help seeking among 15 000 women and men. Hum Reprod 2016;31:2108-18.

- Deshpande PS, Gupta AS. Causes and Prevalence of Factors Causing Infertility in a Public Health Facility. J Hum Reprod Sci 2019;12:287-93.
- 3. Khalaf Y. ABC of subfertility. Tubal subfertility. BMJ 2003;327:610-3.
- Foroozanfard F, Sadat Z. Diagnostic value of hysterosalpingography and laparoscopy for tubal patency in infertile women. Nurs Midwifery Stud 2013;2:188-92.
- Ubeda B, Paraira M, Alert E, Abuin RA. Hysterosalpingography: spectrum of normal variants and nonpathologic findings. AJR Am J Roentgenol 2001;177:131-5.
- Zhang J, Lan W, Wang Y, Chen K, Zhang G, Yang W, et al. Ethiodized poppyseed oil-based contrast medium is superior to water-based contrast medium during hysterosalpingography regarding image quality improvement and fertility enhancement: A multicentric, randomized and controlled trial. EClinicalMedicine 2022;46:101363.
- Watson A, Vandekerckhove P, Lilford R, Vail A, Brosens I, Hughes E. A meta-analysis of the therapeutic role of oil soluble contrast media at hysterosalpingography: a surprising result? Fertil Steril 1994;61:470-7.
- 8. Roest I, Rosielle K, van Welie N, Dreyer K, Bongers M, Mijatovic V, et al. Safety of oil-based contrast medium for hysterosalpingography: a systematic review. Reprod Biomed Online 2021;42:1119-29.
- Fang F, Bai Y, Zhang Y, Faramand A. Oil-based versus water-based contrast for hysterosalpingography in infertile women: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2018;110:153-160.e3.
- Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (Chinese edition). J Chinese Integr Med 2009;7:889-96.
- 11. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
- Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. 2008.
- Alper MM, Garner PR, Spence JE, Quarrington AM. Pregnancy rates after hysterosalpingography with oil- and water-soluble contrast media. Obstet Gynecol 1986;68:6-9.
- de Boer AD, Vemer HM, Willemsen WN, Sanders FB. Oil or aqueous contrast media for hysterosalpingography: a prospective, randomized, clinical study. Eur J Obstet Gynecol Reprod Biol 1988;28:65-8.
- Dreyer K, van Rijswijk J, Mijatovic V, Goddijn M, Verhoeve HR, van Rooij IAJ, et al. Oil-Based or Water-Based Contrast for Hysterosalpingography in Infertile Women. N Engl J Med 2017;376:2043-52.
- Letterie GS, Rose GS. Pregnancy rates after the use of oil-based and water-based contrast media to evaluate tubal patency. South Med J 1990;83:1402-3.
- 17. Lindequist S, Rasmussen F, Larsen C. Use of iotrolan versus ethiodized poppy-seed oil in hysterosalpingography. Radiology 1994;191:513-7.
- Lu J, Qi D, Xu W. Fertility-enhancing effect of oil-based contrast agents during hysterosalpingography and the variation of this effect within a 3-year follow-up period in infertile patients. Front Med 2022;9:1-8.
- Mashaqba, MD, JBOG W Doqom MD, JBOG Naser A. Al-Husban, MD M. Contrast Media In Hysterosalpingogram and It's Effect on Pregnancy Rate 2006. https://www.researchgate.net/publication/315749957\_ Contrast\_Media\_In\_Hysterosalpingogram\_and\_It's\_Effect\_on\_ Pregnancy\_Rate (accessed September 4, 2022).

- Rasmussen F, Lindequist S, Larsen C, Justesen P. Therapeutic effect of hysterosalpingography: oil- versus water-soluble contrast media--a randomized prospective study. Radiology 1991;179:75-8.
- 21. Schwabe MG, Shapiro SS, Haning RV Jr. Hysterosalpingography with oil contrast medium enhances fertility in patients with infertility of unknown etiology. Fertil Steril 1983;40:604-6.
- Spring DB, Barkan HE, Pruyn SC. Potential therapeutic effects of contrast materials in hysterosalpingography: a prospective randomized clinical trial. Kaiser Permanente Infertility Work Group. Radiology 2000;214:53-7.
- Higgins JP, Altman DG. Assessing Risk of Bias in Included Studies. Cochrane Handb. Syst. Rev. Interv. Cochrane B. Ser., Chichester, UK: John Wiley & Sons, Ltd; 2008, p. 187-241.
- 24. Wang R, van Welie N, van Rijswijk J, Johnson NP, Norman RJ, Dreyer K, et al. Effectiveness on fertility outcome of tubal flushing with different contrast media: systematic review and network meta-analysis. Ultrasound Obstet Gynecol 2019;54:172-81.
- Bhoil R, Sood D, Sharma T, Sood S, Sharma J, Kumar N, et al. Contrast Intravasation During Hysterosalpingography. Pol J Radiol 2016;81:236-9.
- Ahmadi F, Haghighi H. Unsuspected pregnancy during hysterosalpingography. Iran J Radiol 2014;11:e5033.
- 27. van Rijswijk J, van Welie N, Dreyer K, Pham CT, Verhoeve HR, Hoek A, et al. Tubal flushing with oil-based or water-based contrast at hysterosalpingography for infertility: long-term reproductive outcomes of a randomized trial. Fertil Steril 2020;114:155-62.
- Satoh M, Aso K, Katagiri Y. Thyroid Dysfunction in Neonates Born to Mothers Who Have Undergone Hysterosalpingography Involving an Oil-Soluble Iodinated Contrast Medium. Horm Res Paediatr 2015;84:370-5.
- 29. van Welie N, Roest I, Portela M, van Rijswijk J, Koks C, Lambalk CB, et al. Thyroid function in neonates conceived after hysterosalpingography with iodinated contrast. Hum Reprod 2020;35:1159-67.

- Zhang Y, Wang H, Pan X, Teng W, Shan Z. Patients with subclinical hypothyroidism before 20 weeks of pregnancy have a higher risk of miscarriage: A systematic review and meta-analysis. PLoS One 2017;12:e0175708.
- Toulis KA, Goulis DG, Venetis CA, Kolibianakis EM, Negro R, Tarlatzis BC, et al. Risk of spontaneous miscarriage in euthyroid women with thyroid autoimmunity undergoing IVF: a meta-analysis. Eur J Endocrinol 2010;162:643-52.
- 32. So S, Yamaguchi W, Tajima H, Nakayama T, Tamura N, Kanayama N, et al. The effect of oil and water-soluble contrast medium in hysterosalpingography on thyroid function. Gynecol Endocrinol 2017;33:682-5.
- 33. van Welie N, Dreyer K, van Rijswijk J, Verhoeve HR, Goddijn M, Nap AW, et al. Treatment effect of oil-based contrast is related to experienced pain at HSG: a post-hoc analysis of the randomised H2Oil study. Hum Reprod 2019;34:2391-8.
- Davies AC, Keightley A, Borthwick-Clarke A, Walters HL. The use of a low-osmolality contrast medium in hysterosalpingography: comparison with a conventional contrast medium. Clin Radiol 1985;36:533-6.
- Hindocha A, Beere L, O'Flynn H, Watson A, Ahmad G. Pain relief in hysterosalpingography. Cochrane Database Syst Rev 2015;2015:CD006106.
- Szymusik I, Grzechocińska B, Marianowski P, Kaczyński B, Wielgoś M. Factors influencing the severity of pain during hysterosalpingography. Int J Gynaecol Obstet 2015;129:118-22.
- 37. De Neubourg D, Janssens L, Verhaegen I, Smits E, Mol BW, Roelant E. Live birth after additional tubal flushing with oil-based contrast versus no additional flushing: a randomised, multicentre, parallel-group pragmatic trial in infertile women with at least one patent tube at hysterosalpingo-foam sonography (HYFOIL study). BMJ Open 2021;11:e054845.
- Exalto N, Emanuel MH. Clinical Aspects of HyFoSy as Tubal Patency Test in Subfertility Workup. Biomed Res Int 2019;2019:1-12.